

## UK: Strict shutdowns to give way to sustained spring recovery

While we expect strict lockdowns to trigger a 3% fall in UK GDP in the first quarter, the more optimistic outlook for vaccinations means a sustained recovery could start in the spring. The longer-term recovery will depend on how quickly government wage support is removed, but also on the drag from lower investment and hiring as a result of new UK-EU trade ties



A deserted Piccadilly Circus in central London


### The short-term outlook

The new, more transmissible Covid-19 strain means the new strict UK lockdown is here to stay for some time. And this inevitably means a negative first quarter for GDP - perhaps in the region of -3%. The upside to that appears limited, given that we know the current lockdown will last until at least mid-February.

That said, the dip is unlikely to be as bad as the first lockdown. Sectors that are able to operate, even partially, are better geared up. And a wider range of industries, including construction/manufacturing, are able to continue operating. Economic activity looks poised to drop to around 15% below its pre-virus level, compared to -25% in the first wave.

The clear downside risk to this comes from Brexit. There are a growing number of reports of firms struggling to move goods across the border now the transition period has ended. The vast majority of hauliers that operate on the key Dover-Calais route are EU-based. The pre-Christmas chaos at the ports appears to have left many reluctant to take UK-bound deliveries, while new customs and VAT processes are adding further complexity.

## Our new UK scenarios for 2021



Source: ING, Macrobond

## The vaccine effect

The UK expects to vaccinate all over 70s (and some other high-risk groups) by mid-February. This may prove over-ambitious, but given the anticipated supply of Oxford/Astrazenica doses, a weekly pace of one to two million doses appears achievable within the next few weeks.

Realistically that could enable a very gradual removal of restrictions from March, and more meaningfully beyond Easter. By then, the hope will be that the hospitalisation risk will have fallen significantly, although the government may feel compelled to reduce wider community transmission further if cases are still high. Our base case is that most, if not all, restrictions have largely gone by the summer months. Like elsewhere, a key risk is that a new variant disrupts the vaccination programme, requiring a tweaked vaccine to be rolled out at speed.

## The strength of the recovery

Pent-up demand is likely, given the savings that have been built up on aggregate through lockdowns. But the more important question is what happens to government support - chiefly wage subsidies. If these are phased out before the worst-affected sectors are back on their feet (think events, travel etc) there is a risk of another increase in unemployment through the middle of the year. An element of this is inevitable, and we think this will prevent a return to the economy's pre-virus size this year or indeed, most likely, for most of 2022.

### Author

**James Smith**

Developed Markets Economist, UK

[james.smith@ing.com](mailto:james.smith@ing.com)

## Disclaimer

This publication has been prepared by the Economic and Financial Analysis Division of ING Bank N.V. ("ING") solely for information purposes without regard to any particular user's investment objectives, financial situation, or means. *ING forms part of ING Group (being for this purpose ING Group N.V. and its subsidiary and affiliated companies)*. The information in the publication is not an investment recommendation and it is not investment, legal or tax advice or an offer or solicitation to purchase or sell any financial instrument. Reasonable care has been taken to ensure that this publication is not untrue or misleading when published, but ING does not represent that it is accurate or complete. ING does not accept any liability for any direct, indirect or consequential loss arising from any use of this publication. Unless otherwise stated, any views, forecasts, or estimates are solely those of the author(s), as of the date of the publication and are subject to change without notice.

The distribution of this publication may be restricted by law or regulation in different jurisdictions and persons into whose possession this publication comes should inform themselves about, and observe, such restrictions.

Copyright and database rights protection exists in this report and it may not be reproduced, distributed or published by any person for any purpose without the prior express consent of ING. All rights are reserved. ING Bank N.V. is authorised by the Dutch Central Bank and supervised by the European Central Bank (ECB), the Dutch Central Bank (DNB) and the Dutch Authority for the Financial Markets (AFM). ING Bank N.V. is incorporated in the Netherlands (Trade Register no. 33031431 Amsterdam). In the United Kingdom this information is approved and/or communicated by ING Bank N.V., London Branch. ING Bank N.V., London Branch is authorised by the Prudential Regulation Authority and is subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. ING Bank N.V., London branch is registered in England (Registration number BR000341) at 8-10 Moorgate, London EC2 6DA. For US Investors: Any person wishing to discuss this report or effect transactions in any security discussed herein should contact ING Financial Markets LLC, which is a member of the NYSE, FINRA and SIPC and part of ING, and which has accepted responsibility for the distribution of this report in the United States under applicable requirements.

Additional information is available on request. For more information about ING Group, please visit [www.ing.com](http://www.ing.com).